This positive feedback was observed in both early (PNT2‐ETV1 cells) and advanced (LNCaP cells) models of ETV1‐driven oncogenic activity, while a link with ERG was not observed in the corresponding ERG‐positive cell models (PNT2‐ERG and VCaP cells), sustaining the potential efficacy of EGFR inhibitors for the treatment of ETV1‐positive prostate carcinomas. Here, ERG is linked to prostate carcinoma.